Service de Neurologie Cognitive, Comportementale et Mouvement anormaux CHU de Toulouse, Hôpital Pierre Paul Riquet, 31059 Toulouse Cedex 9
Toulouse, 31300, France
NCT Number: NCT07578272
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, with a prevalence expected to double by 2040. The diagnosis of PD is often a shock for patients and their families, due to a lack of preparation and adequate support. Progress has been made with the establishment of Parkinson's disease expert centers (PDECs) and better-structured care pathways, but limitations remain. The needs of patients, their caregivers, and neurologists at the time of diagnosis were studied, leading to the development of a flexible, adaptable, and multidisciplinary home-based care pathway. This pathway includes multimodal communication tools (booklet and website) and can also be used by caregivers. The aim is to evaluate this pathway at the departmental level and its ability to prevent the medical, social, and psychosocial risks that complicate the care of patients newly diagnosed with PD. Thus, offering the patient, their caregiver and their neurologist a truly flexible and local care pathway built according to their needs, from the moment the disease is announced, could allow for better acceptance of the disease, an improvement in quality of life, the adoption of beneficial practices as well as a patient-caregiver therapeutic alliance with good adherence to drug and non-drug therapies.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Toulouse, 31300, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For patients:
For caregivers (if the caregiver does not wish to participate, the patient can be included):
Exclusion criteria
For patients
For caregivers
Patients will need to complete questionnaires to establish and evaluate their care pathway.
Caregivers will need to complete questionnaires in order to establish and evaluate the care plan.
Time frame: 6 months after the inclusion
Percentage of patients who adhere to the program, i.e., who accept the partial or complete program according to their needs
Time frame: 6 months after the inclusion
Responses to the quality of life questionnaire at baseline and 6 months post-inclusion
Time frame: 6 months after the inclusion
Caregiver responses to the quality of life questionnaire at baseline and 6 months post-inclusion
Time frame: 6 months after the inclusion
Responses to the satisfaction questionnaire
Contact information is provided by the study sponsor or research team.
University Hospital, Toulouse
Other
Acronym: PRIMS-PARK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716553
Basal Ganglia Diseases, Brain Diseases
Ferrara, Italy
View Trial DetailsNCT06293118
Basal Ganglia Diseases, Brain Diseases
View Trial DetailsNCT04753320
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT07187466
Basal Ganglia Diseases, Brain Diseases
Decatur, Georgia, United States
View Trial Details